SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Four directors were elected to the Federal Home Loan Bank of Boston's board, effective January 1, 2027: Christopher J. Logan and Caroline R. Carpenter as member directors, and Duncan Barnard and Robert Tourigny as independent directors.
View raw filing on EDGAR →Allegiant exercised six aircraft purchase options under its 2021 Boeing purchase agreement, converting them into firm orders for 737-8 aircraft with a list price exceeding $720 million and delivery scheduled for 2028, representing a material capital commitment and expansion of the company's fleet acquisition plan.
View raw filing on EDGAR →Allegiant entered into new employment agreements as of October 22, 2026 with four executive officers (Gregory Anderson, Robert Neal, Drew Wells, and Tyler Hollingsworth) specifying compensatory arrangements including annual base salaries, short-term incentive cash bonus targets (125% to 180% of base salary), long-term incentive stock grants (195% to 300% of base salary), and severance benefits.
View raw filing on EDGAR →The filing discloses Cheniere Energy Partners' declaration of a quarterly cash distribution of $0.890 per common unit payable on November 13, 2026, comprised of a base amount of $0.775 and a variable amount of $0.115. This is a routine but material distribution to unitholders of a publicly traded partnership, directly matching the dividend_distribution event type.
View raw filing on EDGAR →This announcement discloses positive Phase 3 clinical trial results for rinatabart sesutecan (Rina-S®) in platinum-resistant ovarian cancer, meeting primary and key secondary endpoints (PFS and OS with statistically significant improvements). While this is a material clinical milestone for a biotech company's pipeline advancement and regulatory pathway, it does not fit the discrete event categories (not an earnings release, M&A, executive change, or financial obligation). The disclosure is clearly operational/strategic—a major product development milestone—making `operational_other` the most appropriate classification for a material clinical trial success that will inform regulatory discussions and future commercialization strategy.
View raw filing on EDGAR →The 6-K references Exhibit 99.1 titled "Proposed issue of securities - ATH," indicating a planned equity issuance by Alterity Therapeutics. Although the exhibit itself is not furnished in the body, the cover page explicitly lists this as the subject matter being submitted. For a development-stage biotech company, a securities issuance is typically material to investors assessing capital structure and dilution risk.
View raw filing on EDGAR →JAKKS Pacific issued a press release on October 22, 2026 announcing third quarter 2026 financial results, with a teleconference scheduled to discuss the results.
View raw filing on EDGAR →The Board declared a quarterly cash dividend of $0.25 per common share payable on December 28, 2026.
View raw filing on EDGAR →World Acceptance Corporation disclosed fiscal 2027 second quarter financial results for the period ended September 30, 2026, reporting net income of $8.8 million ($1.92 per diluted share) and total revenues of $139.2 million (3.2% increase year-over-year), along with detailed portfolio and operational metrics.
View raw filing on EDGAR →First National Corporation issued a press release on October 23, 2026 reporting consolidated net income of $6.9 million and EPS of $0.76 for Q3 2026, along with year-to-date results of $17.5 million net income and $1.94 EPS. The filing explicitly states this is a disclosure of "financial results for the period ended September 30, 2026" under Item 2.02, with the press release furnished as an exhibit. This is a standard quarterly earnings release with detailed financial highlights, balance sheet data, and operational metrics.
View raw filing on EDGAR →Steele Bancorp issued a press release on October 23, 2026 titled "Steele Bancorp, Inc. Reports Third Quarter 2026 Earnings" disclosing unaudited financial results for the quarter and nine months ended September 30, 2026. The filing includes detailed consolidated balance sheets and statements of income with comparative periods, which is the standard format for quarterly earnings releases under Item 2.02.
View raw filing on EDGAR →The Item 8.01 disclosure centers on two capital allocation actions: (1) Board approval of a new share repurchase program for up to 1,000,000 shares effective November 1, 2026 through October 31, 2027, and (2) declaration of a quarterly cash dividend of $0.27 per share payable November 9, 2026. While both actions are disclosed, the dividend declaration is the more prominent and recurring material event—the Company emphasizes its 111th consecutive quarterly dividend since 1987. Share repurchases, though material, are secondary to the dividend announcement in the narrative structure. The dividend_distribution classification captures the primary disclosed event affecting shareholder returns.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Standex International's Annual Meeting of Stockholders held on October 20, 2026. The filing reports voting outcomes on three proposals: election of three directors (Charles H. Cannon, Jr., David Dunbar, and Michael A. Hickey), an advisory vote on executive compensation, and ratification of Deloitte & Touche, LLP as independent auditors. All three proposals passed with substantial majorities, making this a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →Oak Valley Bancorp disclosed its third-quarter and nine-month 2026 financial results via press release dated October 21, 2026, reporting net income of $6.45 million ($0.77 diluted EPS) for Q3 2026 and $16.87 million ($2.02 diluted EPS) for the nine-month period, along with comprehensive quarterly and nine-month financial highlights and balance sheet data.
View raw filing on EDGAR →Zevia entered into a Securities Purchase Agreement with GP Investments to issue $20 million of Series A Senior Convertible Preferred Stock (15,000 shares at closing, 5,000 shares deferred), convertible into Class A Common Stock at 120% of the 10-day VWAP, subject to a 19.99% conversion cap. The transaction was structured as a private placement under Section 4(a)(2) and Regulation D Rule 506, and the company explicitly acknowledged the dilutive effect on existing shareholders upon conversion.
View raw filing on EDGAR →Aterian entered into an unsecured promissory note with stockholder Chen Zhipeng for up to $1,000,000 in advances at 8.0% annual interest, maturing eight months from October 20, 2026. The note includes conversion features and PIPE participation rights, creating a new direct financial obligation material to the company's capital structure and liquidity.
View raw filing on EDGAR →Picard Medical entered into a Warrant Amendment and Exchange Agreement on October 20, 2026, whereby warrant holders surrendered warrants exercisable for 8,187,766 shares in exchange for 200,000 shares of common stock issued under Section 3(a)(9) exemption. This unregistered equity issuance represents a material dilutive capital event affecting the company's share count and ownership structure.
View raw filing on EDGAR →On October 21, 2026, the Company entered into a Revolving Credit Facility Agreement creating a new direct financial obligation of up to $2,300,000 at 8.5% interest with one-year maturity, formalizing $2,225,000 in prior advances as loans under the agreement with associated covenants.
View raw filing on EDGAR →Ms. Katherine E. Schuelke, a Class III director, resigned from the Board effective October 20, 2026. The disclosure explicitly states her departure from the Board and its committees, with no indication of a replacement appointment. The principal disclosed action is a director leaving office, which is the defining characteristic of exec_departure. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →Michael Braun resigned from the Board of Directors effective June 30, 2026, with no replacement appointed as of the filing date.
View raw filing on EDGAR →The 6-K discloses the poll results of an Extraordinary General Meeting held on October 22, 2026, reporting voting outcomes on four shareholder resolutions. The resolutions include authorization of increased share capital, creation of dual-class share structure with Class B shares carrying 100 votes per share, adoption of amended articles of association, and issuance of 7 million Class B shares to EUG Investment Limited. These structural and capital changes are material to investors' assessment of voting power and ownership structure.
View raw filing on EDGAR →This is a CEO letter to shareholders announcing full-year financial results for the period ended June 30, 2026. The letter discloses material financial metrics including 61.9% revenue growth to HK$135.2 million, a swing to net income of HK$14.6 million (from a prior-year loss of HK$7.9 million), and record performance across all three business segments. The filing explicitly references that "The full results were published yesterday with our Form 20-F for the year ended June 30, 2026," confirming this is a results announcement accompanying the annual report.
View raw filing on EDGAR →CBL International Limited completed a private placement of 400,000 Class B ordinary shares at US$2.12 per share (a 30% discount to market) on October 23, 2026, raising US$848,000 in gross proceeds. The placement also included warrants (Options) to purchase an additional 200,000 shares at US$3.18 per share. This is a classic dilutive unregistered equity issuance under Section 4(a)(2) and Regulation S, materially affecting existing shareholders through immediate dilution and potential further dilution from warrant exercise.
View raw filing on EDGAR →The filing discloses a Charter Amendment increasing authorized shares from 11.3 million to 1.2 billion shares (1 billion common, 200 million preferred), approved by stockholders at the October 5, 2026 annual meeting and filed October 22, 2026. This is a governance event involving amendment to articles of incorporation (Item 5.03). While routine charter amendments may be administrative, a 100x increase in authorized shares is material to investors as it substantially expands the company's capacity for dilutive issuances and capital raises without further shareholder approval.
View raw filing on EDGAR →Gix Internet announced a voluntary delisting of its ordinary shares from the Tel Aviv Stock Exchange (TASE), with the last trading day expected January 25, 2027, and delisting on or about January 27, 2027. While this is a voluntary delisting (not a failure to meet listing standards), it represents a material change in the registrant's listing status and trading venue consolidation. The company will continue trading exclusively on Nasdaq, but the removal from TASE is a significant corporate action affecting shareholder liquidity and market access.
View raw filing on EDGAR →Red Cat Holdings entered into a Business Combination Agreement on October 21, 2026, to acquire all outstanding shares of Steyr Motors AG through a voluntary public cash tender offer at EUR 39.00 per share. The transaction is fully financed and supported by Steyr Motors' anchor shareholder, combining Red Cat's defense customer relationships with Steyr Motors' advanced marine engine technology and European manufacturing capabilities.
View raw filing on EDGAR →The filing's principal disclosure is Reliance Global Group's entry into a non-binding letter of intent (LOI) on September 23, 2026, to acquire substantially all assets of a GPU cloud provider for up to $3.75 million in cash consideration (Item 8.01). This represents a material acquisition activity that would mark the company's entry into the AI infrastructure market and includes a planned rebranding to "GPU Exchange" and ticker change to "XGPU." While the LOI is non-binding as to principal economic terms, the transaction structure, timing, and strategic significance make this a material M&A event that would affect a reasonable investor's assessment of the registrant's business direction and capital deployment.
View raw filing on EDGAR →The filing discloses Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule. Polar Power received a deficiency letter from Nasdaq on May 1, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), and was granted an extension until October 28, 2026, to demonstrate compliance. The company now claims to have regained compliance through multiple equity-raising transactions, but Nasdaq retains discretion to monitor and potentially delist if compliance is not maintained. This is a core delisting-risk disclosure.
View raw filing on EDGAR →The exhibit announces a strategic business restructuring: the Board-approved wind-down and dissolution of mF International's legacy financial trading solutions business (m-Finance Limited and two subsidiaries) with a complete pivot to digital asset operations (Bitcoin Cash treasury, self-mining, and insurance initiatives). This is a material operational and strategic shift that would affect a reasonable investor's assessment of the company's business model and future direction, though it does not fit the specific categories of M&A activity, workforce reduction, or material impairment—it is a deliberate strategic repositioning disclosed as a press release.
View raw filing on EDGAR →Tamar Elkeles, a Board member and Chair of both the Compensation Committee and Nominating and Corporate Governance Committee, tendered her resignation effective immediately on October 19, 2026. While the filing also mentions appointment of two new committee chairs (Admiral Scott Swift and Major General Pete Fesler), the principal disclosed action centers on Dr. Elkeles's departure from the Board. The resignation of a committee chair is material to investors assessing governance and board composition, though the non-disagreement language suggests an orderly transition rather than a conflict-driven departure.
View raw filing on EDGAR →Laser Photonics received a Nasdaq notification on October 20, 2026, that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →The filing discloses that Nasdaq notified Dragonfly on August 20, 2026, of non-compliance with the minimum stockholders' equity requirement (Rule 5550(b)(1)), with stockholders' equity of $(184,000) versus the required $2.5 million minimum. Although the company received an extension through December 31, 2026, to regain compliance, the filing explicitly states that failure to evidence compliance by that date "may be subject to delisting" and that the Staff will provide written notification of delisting if the company does not satisfy the extension terms. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses termination of a material convertible promissory note (the BPOZ Tokeneke Note) for $5 million principal, prepaid in full on October 22, 2026 with accrued interest of $114,904.11. While Item 1.02 addresses "Termination of a Material Definitive Agreement," the substance is a financial event—the early repayment and satisfaction of a debt instrument—rather than a traditional M&A or operational termination. The transaction involves related-party financing (the CEO controls the borrower entity), but the core disclosure is the debt termination itself, which does not fit the specific categories of debt_issuance, covenant_breach, or ma_activity.
View raw filing on EDGAR →The filing discloses a written notice from Nasdaq on October 20, 2026, indicating that the Company's warrants are no longer in compliance with Nasdaq Listing Rule 5452(b)(C) because the aggregate market value of outstanding warrants fell below the required $1 million threshold. The Company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that failure to comply could result in delisting of the warrants. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →Fusemachines amended a Common Stock Purchase Warrant held by Meteora Capital Partners, materially reducing the exercise price from a floor of $0.85 per share to a floating average VWAP price and shortening the warrant term to October 2027. This amendment makes the warrant substantially more likely to be exercised and dilutive to existing shareholders, similar to a dilutive equity issuance. While not a new issuance per se, the amendment of warrant terms to reduce exercise price and increase exercise likelihood is a material capital structure event affecting shareholder dilution.
View raw filing on EDGAR →The exhibit announces the closing of an underwritten public offering of 400,000 ADSs (representing 2.4 million common shares) at US$4.65 per ADS, generating US$1.86 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders and raises capital for the company's exploration activities. The offering was made pursuant to an effective Form F-10 shelf registration statement and represents a material capital-raising event for a mineral exploration company.
View raw filing on EDGAR →HomesToLife announced receipt of a conditional eligibility-to-list letter from Singapore Exchange and issuance of an Introductory Document for a proposed secondary listing on SGX-ST Mainboard. This is a material capital markets milestone reflecting the company's strategic expansion into Asia-Pacific and broadening of its investor base, though completion remains subject to satisfaction of conditions and is not assured. The event is operational/strategic rather than a discrete financial transaction (like debt issuance or M&A), making operational_other the best fit.
View raw filing on EDGAR →The filing discloses an at-the-market (ATM) offering under a Sales Agreement with Needham & Company, LLC, with the Company selling 15,785,757 shares during October 2026 for approximately $4.7 million gross proceeds. This represents a dilutive equity issuance material to investors, as it increases share count by approximately 45% relative to the 19.2 million shares outstanding as of the filing date, and raises capital through unregistered or registered equity sales typical of dilutive issuances.
View raw filing on EDGAR →Akebia received a deficiency notice from Nasdaq on October 21, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing status.
View raw filing on EDGAR →Silver Bow Mining Corp. entered into a First Amendment to an Asset Purchase Agreement dated August 21, 2026, with Montana Goldfields, Inc. and Montana Tunnels Mining, Inc. The Amendment modifies key transaction terms including the Outside Date, the timeline for proxy statement filing, and audited financial statement delivery requirements. This is a material amendment to an underlying asset acquisition transaction that requires shareholder approval, making it a reportable M&A activity under Item 1.01.
View raw filing on EDGAR →YPF announced the early redemption of Class XXXVII Notes (USD 139.5 million at 7% fixed rate, originally maturing May 2027) on November 11, 2026, and simultaneously the issuance of new Class XLIII notes on October 27, 2026, with payment in kind via delivery of USD 4.4 million of Class XXXVII Notes. This is a material refinancing event involving debt restructuring and new debt issuance, though the primary disclosed action is redemption of existing debt rather than creation of a wholly new obligation. The simultaneous issuance of Class XLIII notes and the refinancing structure support classification as a debt capital event.
View raw filing on EDGAR →This is a clear earnings release for Rithm Capital Corp.'s third quarter ended September 30, 2026. The press release discloses GAAP net income of $0.38 per diluted share and earnings available for distribution of $0.55 per diluted share, along with detailed consolidated financial statements (income statement and balance sheet) and business segment highlights. The filing explicitly states this is Item 2.02 disclosure of results of operations and financial condition, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →The disclosure announces the Board-approved appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, effective November 13, 2026, with induction into the Management Council. Although Ravi is a related party (son-in-law of Co-Chairman G V Prasad), the appointment to a senior management role overseeing a major business unit (Aurigene Pharmaceutical Services Ltd., a wholly owned subsidiary) is a material executive appointment that would affect investor assessment of leadership and governance.
View raw filing on EDGAR →This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q2 and H1 FY27 (quarter and six months ended September 30, 2026). It presents comprehensive financial statements including revenues (₹86.7 billion for Q2, ₹167.4 billion for H1), EBITDA, profit before and after tax, EPS, and detailed segment breakdowns. The document explicitly states "Dr. Reddy's Q2 & H1FY27 Financial Results" and includes management commentary from the Co-Chairman & MD. This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →Zachary Ament resigned as Chief Financial Officer effective November 16, 2026, with no disagreement cited. Geoffrey McFarlane was appointed as Interim CFO.
View raw filing on EDGAR →The Company filed a Second Amended and Restated Certificate of Designation for Series C Convertible Preferred Stock, materially reducing the conversion price floor from $4.00 to $1.00 per share and eliminating a prior minimum threshold on Market Price calculation, significantly increasing the dilutive potential of the preferred stock conversion.
View raw filing on EDGAR →The Company disclosed a material modification to rights of security holders, incorporating Item 5.03 by reference regarding amendments to the Certificate of Designation.
View raw filing on EDGAR →The filing discloses the automatic conversion of 372,976 shares of Series A and Series B Convertible Preferred Stock into 8,077,043 shares of Common Stock upon effectiveness of the S-3 registration statement on October 23, 2026. This represents a substantial dilution to existing common shareholders—the outstanding common stock increased from approximately 5.2 million to 13.3 million shares (a 155% increase). While technically a conversion rather than a new issuance, the economic effect is a material dilutive event that would affect a reasonable investor's assessment of ownership and voting power.
View raw filing on EDGAR →This Item 2.04 disclosure reports multiple triggering events that accelerate or increase direct financial obligations: (1) a default notice from Employers Personnel, LLC regarding payment obligations under a service agreement with Lyneer; (2) events of default under the Amended and Restated Loan Agreement with SPP Credit Advisors dated April 29, 2025, with cross-default provisions; and (3) a default notice under the Bridge Loan Agreement dated June 18, 2024. The filing explicitly states that SPP has reserved all rights and remedies under these loan documents, and SLR Business Credit has initiated asset disposition proceedings under UCC Article 9. These are classic covenant breach and cross-default scenarios that materially threaten the registrant's financial obligations and liquidity.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of James River Group's October 22, 2026 annual meeting of shareholders, including voting outcomes for three proposals: election of six directors (Rajiv Basu, Matthew B. Botein, Joel D. Cavaness, Frank N. D'Orazio, Christine LaSala, and Peter B. Migliorato), ratification of Ernst & Young LLP as independent auditor, and advisory approval of 2025 named executive officer compensation. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter are provided, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →